Abstract
Background: Drug‐eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long‐term efficacy of DES in patients with acute myocardial infarction (AMI).
Hypothesis: The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI.
Methods: Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year.
Results: Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 ± 12.7 vs. 18.8 ± 10.6 mm, respectively; p<0.001) and smaller reference diameters (2.97 ± 0.52 vs. 3.19 ± 0.63 mm, respectively, p<0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9%, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7%; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6%; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8%; p = 0.028).
Conclusions: The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.
Keywords: clinical outcome, myocardial infarction, stent
Full Text
The Full Text of this article is available as a PDF (61.0 KB).
References
- 1. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ: Comparison of angioplasty with stenting, with or without abciximab, acute myocardial infarction. N Engl J Med 2002; 346: 957–966 [DOI] [PubMed] [Google Scholar]
- 2. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartollmei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC: Stent primary angioplasty in myocardial infarction study group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 1949–1956 [DOI] [PubMed] [Google Scholar]
- 3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20 [DOI] [PubMed] [Google Scholar]
- 4. Odell A, Dudnason T, Andersson T, Jidbratt H, Grip L: One‐year outcome after percutaneous coronary intervention for stable and unstable angina pectoris with or without application of general usage of stents in unselected European patient groups. Am J Cardiol 2002; 90: 112–118 [DOI] [PubMed] [Google Scholar]
- 5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, for the SIRIUS Investigators : Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323 [DOI] [PubMed] [Google Scholar]
- 6. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, for the TAXUS‐IV Investigators : Polymer‐based, paclitaxel‐eluting stents in patients with coronary artery disease. N Engl J Med 2004; 350: 221–231 [DOI] [PubMed] [Google Scholar]
- 7. Mark DS, Ratko TA, Matuszewski KA, Oinonen MJ, Cummings JP. Clinical and financial impact of drug eluting stents: The US academic experience. J Am Coll Cardiol 2005; 45 (suppl A): 73A [Google Scholar]
- 8. Antman EM, Braunwald E: ST‐elevation myocardial infarction: Pathology, pathophysiology, and clinical features In Braunwald's Heart Disease, 7th ed. (Eds. Zipes DP, Libby P, Bonow RO, Braunwald E.), pp. 1141–1165. Philadelphia: WB Saunders, 2005. [Google Scholar]
- 9. Barbinska A, Markell MS, Salifu MO, Akord M, Ehrlich YH, Kornecki E: Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998; 13: 3153–3159 [DOI] [PubMed] [Google Scholar]
- 10. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP: Comparative study of cyclosporine and tacrolimus vs. newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002; 21: 990–998 [DOI] [PubMed] [Google Scholar]
- 11. Virmani R, Farb A, Kolodgie FD: Histopathologic alterations after endovascular radiation and antiproliferative stents: Similarities and differences. Herz 2002; 27: 1–6 [DOI] [PubMed] [Google Scholar]
- 12. Lemos PA, Saia F, Hoye A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, Feyter P, Domburg RT, Serruys PW: Short‐and long‐term clinical benefit of sirolimus‐eluting stents compared to conventional bare metal stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43: 704–708 [DOI] [PubMed] [Google Scholar]
- 13. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russel ME, Ellis ST, Stone GW: Outcomes with the paclitaxeleluting stent in patient with acute coronary syndromes: Analysis from the TAXUS‐IV trial. J Am Coll Cardiol 2005; 45: 1165–1171 [DOI] [PubMed] [Google Scholar]
- 14. Weber F, Schneider H, Schwarz C, Holzhausen C, Petzsch M, Nienaber CA: Sirolimus‐eluting stents for percutaneous coronary intervention in acute myocardial infarction. Z Kardiol 2004; 93: 938–943 [DOI] [PubMed] [Google Scholar]
- 15. Cheneau E, Rha SW, Kuchulakanti PK, Stabile E, Kinnaird T, Torguson R, Pichard AD, Satler LF, Kent KM, Waksman R: Impact of sirolimus‐eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Cathet Cardiovasc Intervent 2005; 65: 469–472 [DOI] [PubMed] [Google Scholar]
- 16. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW: Two‐year angiographic and intravascular ultrasound follow‐up after implantation of sirolimus‐eluting stents in human coronary arteries. Circulation 2003; 107: 381–383 [DOI] [PubMed] [Google Scholar]
- 17. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, and the STRATEGY Investigators : Tirofiban and sirolimus‐eluting stent vs. abciximab and bare‐metal stent for acute myocardial infarction. J Am Med Assoc 2005; 293: 2109–2117 [DOI] [PubMed] [Google Scholar]
- 18. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, McFadden E, Hofma SH, Giessen WJ, Feyter PJ, Domburg RT, Serruys PW: Sirolimus‐eluting stenting implantation in ST‐elevation acute myocardial infarction. Circulation 2003; 108: 1927–1929 [DOI] [PubMed] [Google Scholar]